ECM Remodeling in Excessive Fibroplasia

过度纤维增生的 ECM 重塑

• 批准号: 7751944
• 负责人: Paul David Benya
• 金额: $ 41.05万
• 依托单位: CHILDREN'S HOSPITAL OF LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-07-01 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7751944
• 关键词: 3-Dimensional; Adherent Culture; Affect; African; Asians; Binding; Biological Process; Cells; Cicatrix; Collagen; Extracellular Matrix; Fibrin; Fibroblasts; Fibrosis; Funding; Gel; Goals; Hispanics; Human; Integrins; Keloid; Laboratory Finding; Lead; Mediating; Molecular; Outcome Measure; Pathway interactions; Patients; Peptide Hydrolases; Peptides; Plasminogen Activator Inhibitor 1; Production; RNA Interference; Regulation; Regulatory Pathway; Research; Skin; Small Interfering RNA; Testing; Therapeutic; Transfection; Validation; Viral; Viral Vector; Vitronectin; Wound Healing; base; in vivo Model; knock-down; member; mutant; overexpression; population based; prevent; repository; success; therapeutic target; tumor

The long term goal of the research is to elucidate the cellular and molecular basis of excess scar formation during wound repair. Keloids are tumor-like skin scars that affect 10 to 20% of people of African decent, Asians, and Hispanics without appropriate treatments. During the past funding period, we used 14 freshly isolated and low passages (<3) strains of normal and keloid fibroblasts from human patients and provided new evidence that (PAI-1) overexpression and elevated collagen accumulation are intrinsic features of keloid fibroblasts. We also provided new and different evidence of a causal relationship between PAI-1 expression and collagen accumulation: adenoviral overexpression and siRNA and shRNAmir suppression demonstrate that PAI-1 produces elevated collagen accumulation in normal and keloid fibroblasts, respectively. Finally, by testing protease-inhibitory and vitronectin-binding mutants of PAI-1 for their capacity to induce collagen accumulation, we found that the latter was equipotent with wild-type PAI-1 and the former was only ~50% effective. Thus, PAI-1 utilizes protease inhibition as well as another of its functions to control collagen accumulation (Tuan et al., 2008, Am J Pathol). The goals of the renewal application are 1) to advance a therapeutic strategy that targets plasminogen activator inhibitor-1 (PAI-1) to control keloid collagen accumulation and prevent or treat keloid formation; 2) to further define and expand the mechanisms utilized by PAI-1 to regulate collagen accumulation in keloid fibroblasts.